Acquisition and Spread of Antimicrobial Resistance : A tet(X) Case Study [PDF]
, 2021 Peer reviewedPublisher ...
Aminov, Rustam
core +1 more source
Characterization of Antibiotic Susceptibility Profiles of Extensively- and Pan-Drug Resistant Acinetobacter Baumannii Clinical Isolates [PDF]
, 2023 Acinetobacter baumannii is an opportunistic pathogen common in intensive care units (ICUs), particularly among immunocompromised individuals. Nosocomial A.
Carabetta, Valerie +5 more
core +1 more source
An Epidemiological and Pharmacokinetic-pharmacodynamic Investigation into the Impact of Carbapenem-resistant Enterobacterales [PDF]
, 2023 Background: According to the 2019 CDC Antibiotic Resistance Threats Report, more than 2.8 million antibiotic-resistant infections occur in the United States each year, leading to more than 35,000 deaths.
Clark, Justin
core +2 more sources
1430. Eravacycline associated hypofibrinogenemia during treatment of M.abscessus
Open Forum Infectious Diseases, 2022 Abstract Background Eravacycline, a novel synthetic fluorocycline, is structurally similar to tigecycline. Cases of tigecycline associated hyperfibrinogenemia have been reported in the literature, however the mechanism is not currently well described.
Rausch, Ethan +3 more
openaire +1 more source
In vitro activity of eravacycline against common ribotypes of Clostridioides difficile [PDF]
Journal of Antimicrobial Chemotherapy, 2020 Abstract Background Eravacycline is a novel synthetic fluorocycline antibacterial approved for complicated intra-abdominal infections. Objectives The purpose of this study was to assess the in vitro activities of eravacycline and ...
Bassères, E +10 more
openaire +3 more sources
C22: Eravacycline versus best previously available therapy in adults with pneumonia due to drug-resistant Acinetobacter baumannii [PDF]
, 2021 There are no published studies documenting outcomes with the use of eravacycline against drug-resistant Acinetobacter baumannii. The purpose of this study is to assess the efficacy of eravacycline use, in comparison to best previously available therapy ...
Jayakumar, Rebecca +3 more
core +1 more source
Antibiotic‐mediated immune modulation in periodontitis
Periodontology 2000, EarlyView.Abstract Periodontitis is a chronic inflammatory disease affecting the supporting structures of the teeth. Although initiated by dysbiotic microbial communities, its progression is largely driven by the host's uncontrolled inflammatory response. While antibiotics have conventionally been employed in periodontitis therapy for their antimicrobial ...
Lina J. Suárez +6 more
wiley +1 more source
Advances in antibiotic therapy in the critically ill [PDF]
, 2016 Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains ...
Antonelli, Massimo +13 more
core +2 more sources
Structure of anhydrotetracycline-bound Tet(X6) reveals the mechanism for inhibition of type 1 tetracycline destructases [PDF]
, 2023 Inactivation of tetracycline antibiotics by tetracycline destructases (TDases) remains a clinical and agricultural threat. TDases can be classified as type 1 Tet(X)-like TDases and type 2 soil-derived TDases.
Blake, Kevin S +6 more
core +2 more sources
Eravacycline for the treatment of complicated intra‐abdominal infections [PDF]
Advances in Digestive Medicine, 2020 AbstractEravacycline is a novel fluorocycline antibiotic in the tetracycline class, with activities against multidrugresistant organisms, extended‐spectrum β‐lactamase‐producing (ESBL) bacteria, and carbapenem‐resistant Enterobacteriaceae. The approval of eravacycline by the U.S.
Hongmei Wang +2 more
openaire +1 more source